Preclinical studies have shown that the candidate, the CD161 inhibitor IMT-009, enhances tumor killing, increases cytokine production, and leads to increased survival rates. The company plans to file an investigational new drug application in the first half of 2022.

"Our single-cell technology platform allows our team to incorporate insights from human biology throughout the discovery and development process, enabling us to rapidly move towards serving patients in need," said Jeffrey Goldberg, CEO of Immunitas.

The company's technology enables rapid target identification and validation in parallel with antibody discovery and engineering.

The series B financing round was led by Agent Capital. The new funding builds on a $39 million series A financing secured by the company in 2019.

Abveris, Immunitas partner on mAbs discovery
Abveris and Immunitas Therapeutics are partnering on the discovery of monoclonal antibodies (mAbs) to expand Immunitas' therapeutic pipeline.